CVRx BeAT-HF trial misses primary endpoint; positive secondary analyses support Barostim label expansion plan

CVRx, Inc.

Trial of 323 HFrEF patients did not reach statistical significance on primary composite endpoint of CV mortality and HF morbidity.
Prespecified analyses favored Barostim: all-cause survival free from LVAD/transplant, Win Ratio analysis, clinical stability.
Safety and symptomatic improvement at 6 months durable through 24 months.
Company plans to submit totality of evidence to FDA for expanded Barostim labeling.
Data to be presented at THT conference on March 21, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.